Supplemental material, sj-docx-1-opp-10.1177_10781552231203186 for Polysorbate 80 as a possible allergenic component in cross-allergy to docetaxel and fosaprepitant: A literature review by Caihong Tang, Yueqiu Zhao, Jing Liu, Xiaoqing Zheng, Xi Guo, Haoying Liu, Licong Chen and Yulan Shi in Journal of Oncology Pharmacy Practice</p
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-14-opp-10.1177_10781552221126102 for Transition to ePrescribing for s...
Supplemental material, sj-docx-1-aop-10.1177_10600280231210275 for Risk of Tendon Injury in Patients...
Supplemental material, sj-docx-1-opp-10.1177_10781552231203723 for Camrelizumab-induced oral licheno...
Supplemental material, sj-docx-1-opp-10.1177_10781552221150936 for Recurrent and atypical immune che...
The increasing use of biotherapeutics across a growing spectrum of neoplastic, autoimmune, and infla...
Supplemental material, sj-docx-1-opp-10.1177_10781552221148118 for VicTAG chemotherapy audit toolkit...
Supplemental material, sj-docx-1-opp-10.1177_10781552231203703 for Cabozantinib-induced heart failur...
Supplemental material, sj-docx-1-cms-10.1177_12034754231220929 for GLP-1R Agonists in Psoriasis Pati...
Supplemental material, sj-docx-1-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-8-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-2-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-6-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-5-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-15-opp-10.1177_10781552221126102 for Transition to ePrescribing for s...
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-14-opp-10.1177_10781552221126102 for Transition to ePrescribing for s...
Supplemental material, sj-docx-1-aop-10.1177_10600280231210275 for Risk of Tendon Injury in Patients...
Supplemental material, sj-docx-1-opp-10.1177_10781552231203723 for Camrelizumab-induced oral licheno...
Supplemental material, sj-docx-1-opp-10.1177_10781552221150936 for Recurrent and atypical immune che...
The increasing use of biotherapeutics across a growing spectrum of neoplastic, autoimmune, and infla...
Supplemental material, sj-docx-1-opp-10.1177_10781552221148118 for VicTAG chemotherapy audit toolkit...
Supplemental material, sj-docx-1-opp-10.1177_10781552231203703 for Cabozantinib-induced heart failur...
Supplemental material, sj-docx-1-cms-10.1177_12034754231220929 for GLP-1R Agonists in Psoriasis Pati...
Supplemental material, sj-docx-1-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-8-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-2-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-6-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-5-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-15-opp-10.1177_10781552221126102 for Transition to ePrescribing for s...
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-14-opp-10.1177_10781552221126102 for Transition to ePrescribing for s...
Supplemental material, sj-docx-1-aop-10.1177_10600280231210275 for Risk of Tendon Injury in Patients...